GSK Wins FDA Accelerated Approval for Nelkarmi in ALK-Positive NSCLC
The FDA granted accelerated approval for Nelkarmi for adults with locally advanced or metastatic ALK-positive NSCLC.
The FDA granted accelerated approval for Nelkarmi for adults with locally advanced or metastatic ALK-positive NSCLC.